Table 1 Predicting inefficacy at 1 and 2 years
Predictor1 year2 years
InefficacyStill onp ValueInefficacyStill onp Value
Number of patients N (%)25 (8)231 (75)49 (16)188 (61)
Female gender N (%)18 (72)147 (64)0.833 (67)117 (62)0.5
Age diagnosis (years)60.6 (53.3–73.1)59.3 (48.3–69)0.3460.6 (52.5–68.6)58.7 (46.9–69.5)0.43
Age MTX onset (years)61.2 (53.9–73.2)60 (50.8–69.8)0.3861.2 (53.1–68.7)59.4 (49.1–70.5)0.55
Symptom duration—prior MTX (months)6.01 (3.35–8.01)6.27 (3.75–12.68)0.386.01 (3.35–7.95)6.09 (3.56–14.59)0.11
RF positive (yes/no)14 (56)94 (41)0.1225 (51)87 (46)0.25
ARA criteria (yes/no)11 (44)121 (52)0.4325 (51)101 (54)0.74
SJC7 (2–10)4 (1–11)0.85 (2–12)5 (1–11)0.72
TJC4 (1–12)5 (1–15)0.944 (0–17)5 (1–13)0.77
28 SJC4 (1–9)4 (1–9)0.844 (1–10)4 (1–9)0.64
28 TJC3 (0–7)3 (0–10)0.283 (0–7)4 (0–10)0.26
Baseline CRP*20 (6–36)13 (5–26)0.3320 (6–38)13 (5–26)0.26
Baseline DAS28*3.7 (2.8–4.7)3.9 (3.0–4.8)0.593.7 (2.8–4.8)4.0 (3.0–4.8)0.67
Baseline HAQ1 (0.375–2)1 (0.5–1.625)0.571.125 (0.5–1.875)1 (0.5–1.625)0.34
SE positive (yes/no)† N (%)21 (91)126 (64)0.00937 (84)99 (63)0.01
Steroids (yes/no)6 (24)39 (17)0.3819 (38)18 (10)0.001
  • ARA, American Rheumatism Association; CRP, C-reactive protein; DAS, disease activity score (using 28 joint counts); HAQ, Health Assessment Questionnaire; MTX, methotrexate; RF, rheumatoid factor; SE, shared epitope; SJC, swollen joint count; TJC, tender joint count.

  • This table illustrates clinical variables in those stopping for inefficacy and those remaining on treatment at 1 and 2 years. Results expressed as median (IQR) unless stated.

  • *293 patients had baseline CRP available and, therefore, could have DAS28 results calculated.

  • †260 patients had DNA samples and were successfully genotyped for SE.